The state of Arizona currently has 5 active clinical trials seeking participants for Primary Biliary Cholangitis research studies. These trials are conducted in various cities, including Phoenix, Tucson, Scottsdale and Mesa.
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
Recruiting
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring of the liver). PBC is a slowly progressive disease, characterised by damage to the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to cirrhosis. PBC may also be associated with multiple symptoms. Many patients with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: Arizona Liver Health, Tucson, Arizona
Conditions: Primary Biliary Cholangitis (PBC)
IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
Recruiting
To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
01/08/2025
Locations: The Institute for Liver Health II LLC dba Arizona Clinical Trials; Arizona Liver Health, Chandler, Arizona
Conditions: Primary Biliary Cholangitis
Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.
Recruiting
Study to investigate the efficacy and safety of two doses of K-808 (pemafribate) in subjects with PBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: UA Thomas D. Boyer Liver Institute, Tucson, Arizona
Conditions: Primary Biliary Cholangitis
A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis.
Recruiting
A Trial to Investigate the Pharmacokinetics (PK) Effects and Safety Profile of K-808 (Pemafibrate) in Primary Biliary Cholangitis (PBC) Subjects with and without Cirrhosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Arizona Liver Health, Chandler, Arizona
Conditions: Primary Biliary Cholangitis, Compensated Cirrhosis
An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Recruiting
The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/11/2024
Locations: Arizona Liver Health, Chandler, Arizona
Conditions: Primary Biliary Cholangitis, Compensated Cirrhosis, Hepatic Impairment